PTO/SB/08a (09-08)
Approved for use through 10/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10766403
Filing Date	2004-01-27
First Named Inventor	Belardinelli
Art Unit	1623
Examiner Name	Crane
Attorney Docket Number	02-479-E

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1 A6	3845770		1974-11-05	Theeuwes et al.	
	2 A6	4326525		1982-04-27	Swanson et al.	
	3 A6	4902514		1990-02-20	Barclay et al.	
	4 A6	4992445		1991-02-12	Lawter et al.	
	5 A6	5001139		1991-03-19	Lawter et al.	
	6 A6	5032252		1991-07-16	Owen et al.	
	7 A6	5616345		1997-04-01	Geoghegan et al.	
	8 A6	6294522		2001-09-25	Zablocki et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.C./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10766403
	Filing Date	2004-01-27
	First Named Inventor	Belardinelli
	Art Unit	1623
	Examiner Name	Crane
	Attorney Docket Number	02-479-E

	9 A6	6322771		2001-11-27	Linden et al.	
	10 A6	6368573		2002-04-09	Leung	
	11 A6	6448235		2002-09-10	Linden et al.	
	12 A6	6552023		2003-22-04	Zablocki	
	13 A6	6599283		2003-07-29	Marzilli et al.	
	14 A6	6605597		2003-12-08	Zablocki et al.	
	15 A6	6677336		2004-01-13	Zablocki	

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1 B6	20020111327		2002-08-25	Linden et al	
	2 B6	20020147174		2002-10-10	Jones et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.C./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10766403
	Filing Date	2004-01-27
	First Named Inventor	Belardinelli
	Art Unit	1623
	Examiner Name	Crane
	Attorney Docket Number	02-479-E

	3 B6	20040137533		2004-07-01	~~Hart et al.~~ Belardinelli et al.	
	4 B6	20070299089		2007-12-27	Belardinelli et al.	
	5 B6	20080170990		2008-07-17	Lieu et al.	
	6 B6	20080213165		2008-09-04	Lieu et al.	
	7 B6	20080267861		2008-10-30	Lieu et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1 C6	WO 99/63938	WO		1999-12-16	Epigenesis Pharm.		☐
	2 C6	WO 05/082379	WO		2005-09-09	Belardinelli et al.		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.C./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10766403
	Filing Date	2004-01-27
	First Named Inventor	Belardinelli
	Art Unit	1623
	Examiner Name	Crane
	Attorney Docket Number	02-479-E

	1 D6	Cerqueira, "The Future of Pharmacologic Stress: Selective A2A Adenosine Receptor Agonists", Am. J. Cardiol. vol 94 (2A), pp. 33D-42D, July 2004	☐
	2 D6	Glover et al. "Characterization of a New, Highly Selective Adenosine A2A Receptor/Agonists with Potential Use in Pharmacologic Stress Perfusion Imaging", Circulation, vol. 110, pp.I-311 (1999)	☐
	3 D6	Hendel et al., "Pharmacologic Stress SPECT Myocardial Perfusion Imaging with a Selective A2A Agonist: Results of a Pilot Study Comparing Adenosine with CVT-3146", Circulation, Supplement IV, Vol. 108, p. IV-636 (2003)	☐
	4 D6	Hendel et al. "Initial Clinical Experience with Regadenoson, a Novel Selective A2A Agonist for Pharmacologic Stress Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging", Journal of the American College of Cardiology, vol. 46, no. 11, pp. 2069-2075 (December 6, 2005)	☐
	5 D6	Kerensky et al. "Dose Dependent Increase in Human Coronary Blood Flow Velocity Following an IV Bolus of CVT-3146, A Novel A2A Adenosine Receptor Agonists: A Potential Agent for the Use in Pharmacological Stress Testing for Myocardial Perfusion Imaging", Circulation, vol. 106, p. II-618 (2002)	☐
	6 D6	Korolkovas, "Essentials of Molecular Pharmacology-Background for Drug Design, Wiley - Interscience, New York, NY, 1970, only pages 266-272 supplied	☐
	7 D6	Kusmic et al., "Coronary microcirculatory vasoconstriction induced by low-flow ischemia in mouse hearts is reversed by an A2A adenosine receptor", FASEB Journal, April 2007, A1227-A1228	☐
	8 D6	Koepfli et al., "Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by PET", European Heart Journal, vo. 27, no. Supp. 1, p. 175 (August 2006)	☐
**	9 D6	Martin et al., "Pharmacology of 2-cylohexylmethylidenehydrazionoadenosine (WRC-0470), a novel, short-acting adenosine A-2A receptor agonist that produces selective coronary vasodilation", Drug Development Research, vol. 40, no. 4, pp. 313-324 (1997).	☐
	10 D6	Riou et al., "Influence of propranolol, enalaprilat, verapamil, and caffeine on adenosine A(2A) receptor medicated coronary vasodilation", Journal of the American College of Cardiology, vol. 40, no. 9, pp. 1687-1690 (November 6, 2002)	☐
**	11 D6	Xu, Jiang, et al. "Coronary vasodilation by a short acting, low affinity A2A adenosine receptor agonist in anesthetize closed chest dogs: a second generation of coronary artery pharmacologic stressor", Circulation, vol. 102, no. 18 p. II 810 (2000)	☐

** Not considered because copy not supplied.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.C./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10766403
	Filing Date	2004-01-27
	First Named Inventor	Belardinelli
	Art Unit	1623
	Examiner Name	Crane
	Attorney Docket Number	02-479-E

	12 D6	Zhao et al., "Effects of caffeine on coronary vasodilation and sinus tachycardia induced by Regadenoson, a novel adenosine A2A receptor agonist, in conscious dogs, "European Heart Journal, vol, 27, no. suppl. 1, p. 424, (August 2006)	☐
	13 D6	Zhao et al., "Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonists" Journal of Cardiovascular Pharmacology, vol. 49, no. 6, pp. 369-375 (June 2007)	☐
	14 D6	Pending U.S. Patent Application Serial No. 12/163,099 filed June 27, 2008	☐

If you wish to add additional non-patent literature document citation information please click the Add button [Add]

EXAMINER SIGNATURE

Examiner Signature	/Lawrence Crane/	Date Considered	02/03/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.C./